LAUREN HOLCOMBE: Open Payments
NPI 1487153839 · CARROLLTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$703 in 36 payments from 13 companies in 2025. Trend: 2023 $965 · 2024 $1,038 · 2025 $703
Food & beverage: $703
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 9 | $162 |
| Novo Nordisk Inc | 5 | $108 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $75 |
| Sumitomo Pharma America, Inc. | 4 | $66 |
| Lilly USA, LLC | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Grifols USA, LLC | 1 | $43 |
| Neurocrine BioSciences, Inc. | 1 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Amgen Inc. | 2 | $30 |
Products named: ELIQUIS, Ozempic, GEMTESA, GLASSIA, Prolastin-C Liquid, OFEV, INGREZZA, JARDIANCE.
Industry payments across GA — which companies pay providers there.
